Mychoice: Testing an Interactive mHealth Tool
NCT03427177 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 257
Last updated 2021-01-27
Summary
Investigators aim to test a culturally diverse and patient guided mHealth decision tool called mychoice, which allows patients to explore their concerns and questions related to clinical trial participation, as well as create a customized and personalized set of questions to enhance patient-provider communication and increase informed decision making. This study employs a mixed-methods approach using both qualitative and quantitative data to evaluate the effectiveness of the mychoice intervention for patients and to explore the provider and organizational factors that impact implementation. A randomized controlled trial will be performed with 270 participants in order to determine the acceptability and feasibility of the intervention, as well as its effects on self-efficacy in discussing clinical trial participation with providers, leading to enhanced informed decision-making. A secondary aim of the study is to evaluate the implementation of the intervention in clinical settings. Implementation evaluation will occur using surveys of medical staff whose patients are participating in the study. These surveys will assess institutional facilitators and barriers to study implementation. Investigators will also conduct cognitive de-briefing interviews after the intervention is completed with key stakeholders at the participating institutions, which will inform a larger implementation study in the future.
Conditions
- Conflict
- Decisional Conflict
Interventions
- BEHAVIORAL
-
mychoice
The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
Sponsors & Collaborators
- collaborator INDUSTRY
- collaborator OTHER
-
Temple University
collaborator OTHER -
Thomas Jefferson University
collaborator OTHER -
Fox Chase Cancer Center
lead OTHER
Principal Investigators
-
Linda Fleisher, PhD · Fox Chase Cancer Center
-
Sarah Bass, PhD · Temple
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-25
- Primary Completion
- 2020-01-21
- Completion
- 2020-02-28
Countries
- United States
Study Locations
More Related Trials
-
Enhancing Cancer Survivorship With Pickleball
NCT06048822 ·Status: COMPLETED ·Phase: NA
-
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051 ·Status: COMPLETED ·Phase: PHASE2
-
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
NCT05142371 ·Status: COMPLETED ·Phase: NA
-
Autoimmunity After Checkpoint Blockade
NCT04119713 ·Status: RECRUITING
-
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
NCT03068637 ·Status: COMPLETED ·Phase: NA
-
Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer
NCT00551889 ·Status: COMPLETED ·Phase: PHASE1
-
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964 ·Status: COMPLETED ·Phase: PHASE1
-
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
NCT00088972 ·Status: TERMINATED ·Phase: PHASE2
-
Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire
NCT05817331 ·Status: COMPLETED
-
A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation
NCT02136524 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738 ·Status: RECRUITING
-
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
NCT03185871 ·Status: WITHDRAWN ·Phase: PHASE2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486 ·Status: RECRUITING ·Phase: PHASE2
-
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
NCT00688168 ·Status: COMPLETED
-
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides
NCT00002557 ·Status: UNKNOWN ·Phase: PHASE2
-
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
NCT00099047 ·Status: COMPLETED ·Phase: PHASE2
-
The Ambient Light Multiple Myeloma Study
NCT05737732 ·Status: RECRUITING ·Phase: NA
-
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
NCT00023621 ·Status: COMPLETED ·Phase: PHASE2
-
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
NCT00002850 ·Status: COMPLETED ·Phase: PHASE3
-
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
NCT00055978 ·Status: COMPLETED ·Phase: PHASE2
-
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
NCT04727294 ·Status: UNKNOWN
-
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
NCT06250335 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
NCT00541164 ·Status: COMPLETED ·Phase: PHASE1/PHASE2